Petros Pharmaceuticals Stock Performance

PTPI Stock  USD 0.01  0.0004  5.00%   
The company holds a Beta of 0.38, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Petros Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Petros Pharmaceuticals is expected to be smaller as well. At this point, Petros Pharmaceuticals has a negative expected return of -0.33%. Please make sure to check Petros Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Petros Pharmaceuticals performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Petros Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
  

Petros Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  1.40  in Petros Pharmaceuticals on November 20, 2025 and sell it today you would lose (0.56) from holding Petros Pharmaceuticals or give up 40.0% of portfolio value over 90 days. Petros Pharmaceuticals is currently does not generate positive expected returns and assumes 10.3291% risk (volatility on return distribution) over the 90 days horizon. In different words, 92% of pink sheets are less volatile than Petros, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Petros Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 13.75 times more volatile than its market benchmark. It trades about -0.03 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.19 per unit of volatility.

Petros Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of Petros Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.01 90 days 0.01 
about 72.95
Based on a normal probability distribution, the odds of Petros Pharmaceuticals to move above the current price in 90 days from now is about 72.95 (This Petros Pharmaceuticals probability density function shows the probability of Petros Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Petros Pharmaceuticals has a beta of 0.38 indicating as returns on the market go up, Petros Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Petros Pharmaceuticals will be expected to be much smaller as well. Additionally Petros Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Petros Pharmaceuticals Price Density   
       Price  

Predictive Modules for Petros Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Petros Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.0110.43
Details
Intrinsic
Valuation
LowRealHigh
0.000.0110.43
Details

Petros Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Petros Pharmaceuticals is not an exception. The market had few large corrections towards the Petros Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Petros Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Petros Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.68
β
Beta against Dow Jones0.38
σ
Overall volatility
0
Ir
Information ratio -0.07

Petros Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Petros Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Petros Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Petros Pharmaceuticals generated a negative expected return over the last 90 days
Petros Pharmaceuticals has high historical volatility and very poor performance
Petros Pharmaceuticals has some characteristics of a very speculative penny stock
Petros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Petros Pharmaceuticalshas  12,345,738  shares shorted by Petros Pharmaceuticals investors is about 500% of outstending shares
The company reported the previous year's revenue of 5.11 M. Net Loss for the year was (14.32 M) with profit before overhead, payroll, taxes, and interest of 3.9 M.
Petros Pharmaceuticals currently holds about 13.3 M in cash with (2.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Petros Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Petros Pink Sheet often depends not only on the future outlook of the current and potential Petros Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Petros Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares OutstandingM
Cash And Short Term Investments3.7 M

Petros Pharmaceuticals Fundamentals Growth

Petros Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Petros Pharmaceuticals, and Petros Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Petros Pink Sheet performance.

About Petros Pharmaceuticals Performance

By evaluating Petros Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Petros Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Petros Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Petros Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.

Things to note about Petros Pharmaceuticals performance evaluation

Checking the ongoing alerts about Petros Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Petros Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Petros Pharmaceuticals generated a negative expected return over the last 90 days
Petros Pharmaceuticals has high historical volatility and very poor performance
Petros Pharmaceuticals has some characteristics of a very speculative penny stock
Petros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Petros Pharmaceuticalshas  12,345,738  shares shorted by Petros Pharmaceuticals investors is about 500% of outstending shares
The company reported the previous year's revenue of 5.11 M. Net Loss for the year was (14.32 M) with profit before overhead, payroll, taxes, and interest of 3.9 M.
Petros Pharmaceuticals currently holds about 13.3 M in cash with (2.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Petros Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Petros Pharmaceuticals' pink sheet performance include:
  • Analyzing Petros Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Petros Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Petros Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Petros Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Petros Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Petros Pharmaceuticals' pink sheet. These opinions can provide insight into Petros Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Petros Pharmaceuticals' pink sheet performance is not an exact science, and many factors can impact Petros Pharmaceuticals' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Petros Pink Sheet analysis

When running Petros Pharmaceuticals' price analysis, check to measure Petros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Petros Pharmaceuticals is operating at the current time. Most of Petros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Petros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Petros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Petros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities